CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 40 enrolled
Drug / intervention
EVICEL® Fibrin Sealant +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02227706
NCT02227706Phase 3Completed

A Prospective, Randomized, Controlled Study Evaluating EVICEL® Fibrin Sealant as an Adjunct to Haemostasis During Abdominal, Retroperitoneal, Pelvic or Thoracic (Non-Cardiac) Surgery in Paediatric Patients

Ethicon, Inc.·interventional·Posted Aug 28, 2014·Updated Aug 31, 2020

In Brief

A Phase 3 clinical trial evaluating EVICEL® Fibrin Sealant and SURGICEL® Absorbable Hemostat for Hemorrhage and Soft Tissue Bleeding. Completed, enrolled 40 participants across 13 sites in 3 countries.

Detailed Summary

To evaluate the safety and effectiveness of EVICEL® Fibrin Sealant (Human) as an adjunct to achieve haemostasis during surgery in paediatric patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Canada, United Kingdom
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 28, 2014
Enrollment StartAug 1, 2014
Primary CompletionApr 17, 2019
Study CompletionMay 17, 2019
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 11.8 years ago

Interventions

EVICEL® Fibrin Sealantbiological

EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product

SURGICEL® Absorbable Hemostatdevice

SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.